CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Fenofibrate tablets, 48 mg and 145 mg, which is an AB-rated equivalent to Tricor® by Abbvie.
Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. According to IQVIA, total market sales for Fenofibrate tablets for the last twelve months ending January 2019 were $91.1 million.
Solco Healthcare will market Fenofibrate tablets in 90 count bottles for both strengths. Solco anticipates launching this product in the very near future. Please contact your Solco Healthcare National Accounts Director or customer service at 1-888-869-8008 for more information.